Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onartuzumab + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Onartuzumab + paclitaxel is a combination therapy consisting of onartuzumab, a recombinant humanized monoclonal antibody targeting the MET receptor (also known as hepatocyte growth factor receptor), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. Onartuzumab inhibits the MET signaling pathway by binding to the extracellular domain of the MET receptor, thereby blocking its activation by hepatocyte growth factor (HGF). Paclitaxel disrupts cell division by stabilizing microtubules and preventing their depolymerization. This combination has been investigated in clinical trials for advanced solid tumors such as triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). Clinical studies have not demonstrated significant improvement in progression-free or overall survival with this combination compared to standard regimens; increased rates of certain adverse events such as edema and hypoalbuminemia were observed in onartuzumab-containing arms[1][3][6][10].
- Other names
- Onartuzumab + paclitaxel
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on onartuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onartuzumab + paclitaxel.